Latest Medtech News
P&F Products & Features GmbH has acquired AVVie GmbH, adding the AngelValve™ Augmentation System to its structural heart portfolio and strengthening its focus on next-generation transcatheter therapies.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
Developed for the treatment of mitral regurgitation, AngelValve is a transcatheter platform designed to address unmet needs among patients with limited or no treatment options. The acquisition combines AVVie’s technology and intellectual property with P&F’s expertise in product development, clinical and regulatory activities, manufacturing, and commercialization to accelerate the platform’s development.
“This acquisition represents another important step toward our vision of becoming a global leader in structural heart therapy,” said Katharina Kiss, MD, CEO of P&F. “By combining AVVie’s engineering excellence with P&F’s expertise in clinical trial development and regulatory execution, we are well positioned to advance the AngelValve™ platform and deliver meaningful innovation for physicians and patients worldwide.”
